Fibroblast growth factor 21 ameliorates neurodegeneration in rat and cellular models of Alzheimer’s disease
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Our understanding of the mechanisms underlying process in Alzheimer's disease (AD) is far from completion and new therapeutic targets are urgently needed. Recently, the link between dementia and diabetes mellitus (DM) prompted us to search for new therapeutic strategies from glucose metabolism regulators for neurodegeneration. Previous studies have indicated that fibroblast growth factor 21 (FGF21), an attractive and potential therapeutic treatment for DM, may exert diverse effects in the central nervous system. However, the specific biological function and mechanisms of FGF21 on AD is still largely unknown. We report here a study in vivo and in vitro of the neuroprotective effects of FGF21 on cell apoptosis, tau hyperphosphorylation and oxidative stress induced by amyloid β-peptide 25-35. In the present study, the results also further provided evidence for molecular mechanisms by which FGF21 exerted its beneficial effects in neuron and suggested that the regulation of protein phosphatase 2A / mitogen-activated protein kinases / hypoxia-inducible factor-1α pathway may play a key role in mediating the neuroprotective effects of FGF21 against AD-like pathologies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2016 Alzheimer's disease facts and figures
Alzheimer's Association (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.001 · Cited by 5,069
Querfurth, H. W., & LaFerla, F. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0909142 · Cited by 4,569
2018 Alzheimer's disease facts and figures
Alzheimer's Association (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.001 · Cited by 1,912
Oxidative Damage Is the Earliest Event in Alzheimer Disease
Nunomura, A., Perry, G., Aliev, G., Hirai, K., Takeda, A., Balraj, E. K., Jones, P. K., Ghanbari, H., Wataya, T., Shimohama, S., et al. (2001) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/60.8.759 · Cited by 1,885 · cited 1×
“As to mitochondrial oxidative damage, it is also closely related to the pathogenesis of AD [31], and it is even considered as one of the earliest manifestations of AD [32,33].”
BackgroundYu, T., Robotham, J. L., & Yoon, Y. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0511154103 · Cited by 1,246 · cited 1×
“Studies have shown that the excessive production of ROS will cause obvious biological damage to mitochondria when oxidative stress occurs [34,35].”
BackgroundXu, J., Lloyd, D. J., Hale, C., Stanislaus, S., Chen, M., Sivits, G., Vonderfecht, S., Hecht, R., Li, Y.-S., Lindberg, R. A., et al. (2009) · Diabetes · doi:10.2337/db08-0392 · Cited by 1,151
Mitochondria, oxygen free radicals, disease and ageing
Raha, S., & Robinson, B. H. (2000) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(00)01674-1 · Cited by 1,066
Fon Tacer, K., Bookout, A. L., Ding, X., Kurosu, H., John, G. B., Wang, L., Goetz, R., Mohammadi, M., Kuro-o, M., Mangelsdorf, D. J., et al. (2010) · Molecular Endocrinology · doi:10.1210/me.2010-0142 · Cited by 700
Lin, Z., Tian, H., Lam, K. S. L., Lin, S., Hoo, R. C. L., Konishi, M., Itoh, N., Wang, Y., Bornstein, S. R., Xu, A., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.005 · Cited by 691 · cited 1×
“As a metabolism regulator, the effects of FGF21 on glucose homeostasis and insulin sensitivity have been shown in previous reports [51,52].”
ResultSelf-citationBaker, L. D., Cross, D. J., Minoshima, S., Belongia, D., Watson, G. S., & Craft, S. (2011) · Archives of Neurology · doi:10.1001/archneurol.2010.225 · Cited by 639
Cited by
The Potential Role of Cytokines and Growth Factors in the Pathogenesis of Alzheimer’s Disease
Ogunmokun, G., Dewanjee, S., Chakraborty, P., Valupadas, C., Chaudhary, A., Kolli, V., Anand, U., Vallamkondu, J., Goel, P., Paluru, H. P. R., et al. (2021) · Cells · doi:10.3390/cells10102790 · Cited by 85
“In the rat models, FGF-21 has been found to ameliorate Aβ peptide-mediated neurodegeneration [83].”
BackgroundPhysical Exercise-Induced Myokines in Neurodegenerative Diseases
Lee, B., Shin, M., Park, Y., Won, S.-Y., & Cho, K. S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115795 · Cited by 79
“Myokine ND Function Mechanism Model Reference PD Antioxidative stress GSH ↑ Primary rat embryonic mesencephalic culturestreated with 6-OHDA and FGF2 [280] Decreased cell death MEK/ERK1/2 signaling pathway ↑ BAD phosphorylation ↑ AIF translocation ↓ PI3K/Akt signaling pathway ↑ SH-SY5Y cells treated with rotenone and F…”
BackgroundInfluentialGuo, M., Zhu, F., Qiu, W., Qiao, G., Law, B. Y.-K., Yu, L., Wu, J., Tang, Y., Yu, C., Qin, D., et al. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.08.030 · Cited by 72
Targeting Alzheimer’s Disease: The Critical Crosstalk between the Liver and Brain
Huang, Z., Lin, H. W. (., Zhang, Q., & Zong, X. (2022) · Nutrients · doi:10.3390/nu14204298 · Cited by 50
(2020) · Advances in clinical chemistry · doi:10.1016/bs.acc.2019.07.012 · Cited by 46
Metadata
- Authors
- Chen, S., Chen, S.-T., Sun, Y., Xu, Z., Wang, Y., Yao, S.-Y., Yao, W.-B., & Gao, X.-D.
- Venue
- Redox Biology
- Publisher
- Elsevier BV
- Published
- 2019-04
- Volume
- 22
- Pages
- 101133
- ISSN
- 2213-2317 (ISSN-L)
- OpenAlex
- W2911455987
- Cited by
- 119
- References
- 19
- FWCI
- 7.14
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fibroblast growth factor 21 ameliorates neurodegeneration in rat and cellular models of Alzheimer’s disease. https://app.cochat.ai/papers/10.1016/j.redox.2019.101133
- The paper
- Chen, S., Chen, S.-T., Sun, Y., Xu, Z., Wang, Y., Yao, S.-Y., Yao, W.-B., & Gao, X.-D. (2019). Fibroblast growth factor 21 ameliorates neurodegeneration in rat and cellular models of Alzheimer’s disease. Redox Biology. https://doi.org/10.1016/j.redox.2019.101133
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.